LCS3|CAS 109844-92-0|DC Chemicals

Cas No.:	109844-92-0
Chemical Name:	N-(4-chlorophenyl)-5-nitro-2-furamide
Synonyms:	N-(4-chlorophenyl)-5-nitro-2-furamide
SMILES:	ClC1=CC=C(NC(C2=CC=C([N+]([O-])=O)O2)=O)C=C1
Formula:	C₁₁H₇N₂O₄Cl
M.Wt:	266.637
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	LCS3 inhibits glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) (IC50=3.3 µM and 3.8 µM, respectively) synergistically. LCS3 shows anti-tumor activity, and induces apoptosis. LCS3 can be used in lung adenocarcinoma (LUAD) research.
In Vitro:	LCS3 (5 nM-10 µM; 96 h) inhibits lung cancer cell lines, but not non-transformed lung cells[1]. LCS3 (3 µM; 96 h) selectively kills lung adenocarcinoma (LUAD) cell lines, in part through the induction of apoptosis[1]. LCS3 induces ROS and NRF2 pathway activation in sensitive lung adenocarcinoma (LUAD) cells[1]. Cell Viability Assay[1] Cell Line: Non-small cell lung cancer (NSCLC) cells and non-transformed lung cells Concentration: 5 nM-10 µM Incubation Time: 96 hours Result: Inhibited the growth of 24/25 NSCLC cell lines at low micromolar concentrations (IC50<5 µM), both of the non-transformed lung cell lines were relatively insensitive (IC50>10 µM). Apoptosis Analysis[1] Cell Line: lung adenocarcinoma (LUAD) cells Concentration: 3 µM Incubation Time: 96 hours Result: Increased cleavage of caspase 3, caspase 7 and/or PARP1 in all LCS3-sensitive LUAD cell lines. Cell Viability Assay[1] Cell Line: H23 and H1650 cells Concentration: 3 µM Incubation Time: 3, 6, and 12 hours Result: Responded to LCS3 by accumulating ROS and activating the NRF2 transcription program.
References:	[1]. Fraser D Johnson, et al. Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells. Cell Rep. 2022 Feb 8;38(6):110343.

Cat. No.	Product name	Field of application
DC59120	BTSA1.2	BTSA1.2 is a rationalized BTSA1 analog with improved binding to BAX, cellular cytotoxicity, and better toleratence in vivo. Combination of BTSA1.2 with Navitoclax demonstrates synergistic efficacy in apoptosis-resistant cancer cells, xenografts, and patient-derived tumors while sparing healthy tissues.
DC74585	N6F11	N6F11 is a ferroptosis inducer, and can trigger the degradation of glutathione peroxidase 4 (GPX4) specifically in cancer cells. N6F11 can be used for ferroptosis study.
DC73134	GNE-684	GNE-684 is a potent, cross-species, specific RIP1 kinase (RIPK1) inhibitor with IC50 of 21, 189 and 691 nM for human, mouse and rat RIP1, respectively.
DC73130	AC-003	AC-003 is a novel, orally administered small-molecule inhibitor targeting receptor-interacting protein kinase 1 (RIPK1), demonstrating therapeutic potential for the treatment of idiopathic pulmonary fibrosis (IPF).
DC73120	J012-3168	RPL11-MDM2 inhibitor S9 (J012-3168) is a small-molecule RPL11 mimetic and potential inhibitor of RPL11-MDM2 interaction, directly binds MDM2 and induces p53 stabilization and activation.
DC73117	BAY 1892005	BAY 1892005 is a small molecule that modulate mutant p53 condensation and nuclear accumulation, binds covalently to mutant p53R175H and p53Y220C and shows stabilization of p53WT and p53Y220C, exhibits anti-proliferative activity in a set of cell lines wit
DC73115	DEBIO 1143	DEBIO 1143 (Xevinapant, AT-406, SM406, ARRY-334543, D1143) is a potent, orally active Smac mimetic that antagonizes cIAP1, cIAP2 and XIAP with Ki of 66.4, 1.9 and 5.1 nM, respectively.
DC73101	GSK137	GSK137 is a potent, small-molecule BCL6 inhibitor binding to BCL6 BTB-POZ domain, displaces peptides derived from the human SMRT co-repressor from the BCL6 BTB-POZ domain in a TR-FRET assay with a pIC50 of 8.0.
DC72891	CWI1-2 hydrochloride	CWI1-2 hydrochloride is an inhibitor of IGF2BP2 that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.
DC72584	M47	M47 is a small molecule that selectively destabilizes Cryptochrome 1 (CRY1) and increases degradation of the CRY1 in the nucleus. M47 enhances apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and enhances life span in p53 knockout mice. M47 can be used in research of cancer.